Literature DB >> 12509979

Cloning, expression, purification, and crystallisation of HIV-2 reverse transcriptase.

Louise E Bird1, Philip P Chamberlain, Guillaume B E Stewart-Jones, Jingshan Ren, David I Stuart, David K Stammers.   

Abstract

A purification procedure is described for the isolation of recombinant HIV-2 reverse transcriptase expressed in Escherichia coli. The p68 subunit is expressed, in the absence of induction, and use of a heparin-Sepharose column produces substantially pure protein. Concentration of the homodimeric p68 reverse transcriptase pool, followed by incubation at room temperature for several days, results in full conversion by E. coli proteases to the heterodimer (p68/p55). This extended incubation simplifies the purification process and improves the yield of heterodimeric reverse transcriptase, which shows a truncation of the smaller subunit to 427 residues. The protein is then purified further by hydroxyapatite and gel-filtration chromatography to homogeneity. The HIV-2 RT is active and has been used to produce crystals that diffract to beyond 3.0 A.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12509979     DOI: 10.1016/s1046-5928(02)00567-3

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  3 in total

Review 1.  Retroviral reverse transcriptases.

Authors:  Alon Herschhorn; Amnon Hizi
Journal:  Cell Mol Life Sci       Date:  2010-04-01       Impact factor: 9.261

2.  The phenylmethylthiazolylthiourea nonnucleoside reverse transcriptase (RT) inhibitor MSK-076 selects for a resistance mutation in the active site of human immunodeficiency virus type 2 RT.

Authors:  Joeri Auwerx; Miguel Stevens; An R Van Rompay; Louise E Bird; Jingshan Ren; Erik De Clercq; Bo Oberg; David K Stammers; Anna Karlsson; Jan Balzarini
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

3.  Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance?

Authors:  Paul L Boyer; Stefan G Sarafianos; Patrick K Clark; Eddy Arnold; Stephen H Hughes
Journal:  PLoS Pathog       Date:  2006-02-17       Impact factor: 6.823

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.